Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.
A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.
Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.
Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.
Prostate cancer and prostatic diseases. 2024 Jul 05 [Epub ahead of print]
Neal Shore, Jason Hafron, Daniel Saltzstein, Amitabha Bhaumik, Pankaj Aggarwal, Jennifer Phillips, Tracy McGowan
Carolina Urologic Research Center, Myrtle Beach, SC, USA. ., Michigan Institute of Urology, West Bloomfield, MI, USA., Urology San Antonio, San Antonio, TX, USA., Janssen Research and Development, Titusville, NJ, USA., Janssen Medical Affairs, Horsham, PA, USA.